Additionally, repurposing BACE1 inhibitors currently undergoing clinical trials for AD for moderation of peripheral Aβ levels could be a novel therapy for vascular dysfunction induced by metabolic disease. This evidence concerns the gene BACE1 and Alzheimer disease.